Jiang YZ - Search Results

1

CCL19⁺ dendritic cells potentiate clinical benefit of anti-PD-(L)1 immunotherapy in triple-negative breast cancer.

Wu SY, Zhang SW, Ma D, Xiao Y, Liu Y, Chen L, Song XQ, Ma XY, Xu Y, Chai WJ, Jin X, Shao ZM, Jiang YZ. Wu SY, et al. Among authors: jiang yz. Med. 2023 Jun 9;4(6):373-393.e8. doi: 10.1016/j.medj.2023.04.008. Epub 2023 May 17. Med. 2023. PMID: 37201522 Free article.

2

Effect of large tumor size on cancer-specific mortality in node-negative breast cancer.

Yu KD, Jiang YZ, Chen S, Cao ZG, Wu J, Shen ZZ, Shao ZM. Yu KD, et al. Among authors: jiang yz. Mayo Clin Proc. 2012 Dec;87(12):1171-80. doi: 10.1016/j.mayocp.2012.07.023. Mayo Clin Proc. 2012. PMID: 23218085 Free PMC article.

3

The residual tumor autophagy marker LC3B serves as a prognostic marker in local advanced breast cancer after neoadjuvant chemotherapy.

Chen S, Jiang YZ, Huang L, Zhou RJ, Yu KD, Liu Y, Shao ZM. Chen S, et al. Among authors: jiang yz. Clin Cancer Res. 2013 Dec 15;19(24):6853-62. doi: 10.1158/1078-0432.CCR-13-1617. Epub 2013 Oct 18. Clin Cancer Res. 2013. PMID: 24141623

4

Immediate postmastectomy breast reconstruction showed limited advantage in patient survival after stratifying by family income.

Jiang YZ, Liu YR, Yu KD, Zuo WJ, Shao ZM. Jiang YZ, et al. PLoS One. 2013 Dec 12;8(12):e82807. doi: 10.1371/journal.pone.0082807. eCollection 2013. PLoS One. 2013. PMID: 24349366 Free PMC article.

5

GATA3 mutations define a unique subtype of luminal-like breast cancer with improved survival.

Jiang YZ, Yu KD, Zuo WJ, Peng WT, Shao ZM. Jiang YZ, et al. Cancer. 2014 May 1;120(9):1329-37. doi: 10.1002/cncr.28566. Epub 2014 Jan 29. Cancer. 2014. PMID: 24477928 Free article.

6

Preoperative measurement of breast cancer overestimates tumor size compared to pathological measurement.

Jiang YZ, Xia C, Peng WT, Yu KD, Zhuang ZG, Shao ZM. Jiang YZ, et al. PLoS One. 2014 Jan 29;9(1):e86676. doi: 10.1371/journal.pone.0086676. eCollection 2014. PLoS One. 2014. PMID: 24489766 Free PMC article.

7

The effect of laterality and primary tumor site on cancer-specific mortality in breast cancer: a SEER population-based study.

Bao J, Yu KD, Jiang YZ, Shao ZM, Di GH. Bao J, et al. Among authors: jiang yz. PLoS One. 2014 Apr 16;9(4):e94815. doi: 10.1371/journal.pone.0094815. eCollection 2014. PLoS One. 2014. PMID: 24740002 Free PMC article.

8

PIK3CA mutations define favorable prognostic biomarkers in operable breast cancer: a systematic review and meta-analysis.

Liu YR, Jiang YZ, Zuo WJ, Yu KD, Shao ZM. Liu YR, et al. Among authors: jiang yz. Onco Targets Ther. 2014 Apr 10;7:543-52. doi: 10.2147/OTT.S60115. eCollection 2014. Onco Targets Ther. 2014. PMID: 24748804 Free PMC article.

9

Elevated expression of Girdin in the nucleus indicates worse prognosis for patients with estrogen receptor-positive breast cancer.

Peng WT, Hu X, Yao L, Jiang YZ, Shao ZM. Peng WT, et al. Among authors: jiang yz. Ann Surg Oncol. 2014 Dec;21 Suppl 4:S648-56. doi: 10.1245/s10434-014-3746-y. Epub 2014 May 3. Ann Surg Oncol. 2014. PMID: 24793340

10

Enriched variations in TEKT4 and breast cancer resistance to paclitaxel.

Jiang YZ, Yu KD, Peng WT, Di GH, Wu J, Liu GY, Shao ZM. Jiang YZ, et al. Nat Commun. 2014 May 13;5:3802. doi: 10.1038/ncomms4802. Nat Commun. 2014. PMID: 24823476 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

455 results

Search Page

Filters